<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00228813</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00021819</org_study_id>
    <secondary_id>0159-2004</secondary_id>
    <nct_id>NCT00228813</nct_id>
  </id_info>
  <brief_title>G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome</brief_title>
  <acronym>G-CSF PMRD</acronym>
  <official_title>Feasibility Study of Using G-CSF Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome With Partially Mismatched Related Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:&#xD;
&#xD;
        -  To examine the engraftment rate in patients receiving in vivo T-cell-depleted G-CSF&#xD;
           stimulated bone marrow from partially mismatched related donors.&#xD;
&#xD;
        -  To evaluate the incidence and severity of acute and chronic graft-versus-host disease in&#xD;
           patients receiving in vivo T-cell-depleted G-CSF stimulated bone marrow from partially&#xD;
           mismatched related donors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-arm, non-randomized feasibility study. Patients meeting the criteria&#xD;
      for this study will be entered sequentially until completion or closure of the study. Early&#xD;
      stopping rules will be employed to ascertain whether an unacceptable rate of toxicity&#xD;
      (non-engraftment, and/or acute GVHD) occurs.&#xD;
&#xD;
      Patients will be prepared for transplant through the administration of the following&#xD;
      conditioning regimen based on their primary disease:&#xD;
&#xD;
        -  Total body irradiation (1400 rads in 8 fractionated doses) and high dose chemotherapy,&#xD;
           including cytosine arabinoside, etoposide, and cyclophosphamide. Patients with bone&#xD;
           marrow failure syndrome will not receive etoposide in the conditioning regimen.&#xD;
&#xD;
        -  Post transplant immunosuppression prophylaxis against acute GVHD will include sequential&#xD;
           administration of cyclosporine, methotrexate, basiliximab and mycophenolate.&#xD;
&#xD;
        -  The donor will receive 3 daily G-CSF injections prior to marrow harvest starting on day&#xD;
           -3. The injections may be initiated by the donor's primary physician prior to donor's&#xD;
           arrival, or by the BMT service at Children's Healthcare of Atlanta.&#xD;
&#xD;
        -  Patients will receive daily GM-CSF injections (250 mcg/m2) starting from day +7 post&#xD;
           transplant until absolute neutrophil count (ANC) is greater than 2,000/µL for three&#xD;
           days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of enrollment&#xD;
  </why_stopped>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment Rate</measure>
    <time_frame>Day 45</time_frame>
    <description>The number of participants who received in vivo T-cell-depleted G-CSF stimulated bone marrow from partially mismatched related donor who reached engraftment by Day 45.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Acute Graft-versus-host Disease</measure>
    <time_frame>Day 100</time_frame>
    <description>The number of participants diagnosed with new acute graft-versus-host disease (GVHD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Chronic Graft-versus-host Disease</measure>
    <time_frame>Duration of Study (Up to two years)</time_frame>
    <description>The number of participants diagnosed with chronic graft-versus-host disease (GVHD).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Granulocyte Colony Stimulating Factor (G-CSF) stimulation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive bone marrow from donors who undergo Granulocyte Colony Stimulating Factor (G-CSF) stimulation prior to bone marrow collection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Colony Stimulating Factor</intervention_name>
    <description>FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.&#xD;
Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.&#xD;
Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.&#xD;
Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.&#xD;
Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection</description>
    <arm_group_label>Granulocyte Colony Stimulating Factor (G-CSF) stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with hematologic malignancies or bone marrow failure syndrome who are&#xD;
             candidates for allogeneic bone marrow transplantation are eligible for this study.&#xD;
             Hematologic malignancies indicated for transplantation:&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL) in first remission (with high risk feature),&#xD;
                  2nd or greater remission.&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) in first remission (with high risk feature), 2nd or&#xD;
                  greater remission.&#xD;
&#xD;
               -  Chronic myeloid leukemia (CML) in 2nd chronic phase or accelerated phase.&#xD;
&#xD;
               -  Juvenile myelomonocytic leukemia (JMML).&#xD;
&#xD;
               -  Myelodysplastic syndrome.&#xD;
&#xD;
               -  Biphenotypic leukemia in first (with high risk feature), 2nd or greater&#xD;
                  remission.&#xD;
&#xD;
               -  Induction failure leukemia.&#xD;
&#xD;
               -  Refractory relapsed leukemia.&#xD;
&#xD;
               -  Bone marrow failure syndrome.&#xD;
&#xD;
               -  Severe aplastic anemia failed immunotherapy.&#xD;
&#xD;
          -  Patients who do not have a 6 out of 6 matched related or unrelated donor or 4/6 and&#xD;
             5/6 matched cord blood will be eligible for this study.&#xD;
&#xD;
          -  Partially mismatched related donor availability as defined by molecular typing with 3&#xD;
             to 5 HLA matches.&#xD;
&#xD;
          -  Patients who are under 22 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will not be excluded based on sex, racial, or ethnic background.&#xD;
&#xD;
          -  Patients will be excluded if they demonstrate significant functional deficits in major&#xD;
             organs, which would obviously interfere with successful outcome following bone marrow&#xD;
             transplant utilizing the following guidelines.&#xD;
&#xD;
               -  Evidence of active, deep-seated, life-threatening infections for which there is&#xD;
                  no known effective therapy (certain fungal species, HIV, etc.).&#xD;
&#xD;
               -  Patients who have been treated for infections must have appropriate responses as&#xD;
                  documented by 2 (two) consecutive negative cultures and/or stable radiographic&#xD;
                  examinations.&#xD;
&#xD;
               -  Patients who have active central nervous system (CNS) leukemic disease.&#xD;
&#xD;
          -  Patients will be excluded if they are women of childbearing potential who are&#xD;
             currently pregnant (beta-HCG+) or who are not practicing adequate contraception.&#xD;
&#xD;
          -  Patients who have had a previous hematopoietic stem cell transplant will be excluded.&#xD;
&#xD;
          -  Donors will be excluded if they are sensitive to E. coli-derived protein.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuang-Yueh Chiang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Healthcare of Atlanta/Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2005</study_first_posted>
  <results_first_submitted>March 23, 2016</results_first_submitted>
  <results_first_submitted_qc>May 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 6, 2016</results_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from Children's Healthcare of Atlanta between January 2005 and December 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Granulocyte Colony Stimulating Factor (G-CSF) Stimulation</title>
          <description>Participants with hematologic malignancies or bone marrow failure syndrome received in vivo T-cell depleted granulocyte colony stimulating factor (G-CSF) stimulated bone marrow from a partially mismatched related donor.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Granulocyte Colony Stimulating Factor (G-CSF) Stimulation</title>
          <description>Participants with hematologic malignancies or bone marrow failure syndrome received in vivo T-cell depleted granulocyte colony stimulating factor (G-CSF) stimulated bone marrow from a partially mismatched related donor.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Engraftment Rate</title>
        <description>The number of participants who received in vivo T-cell-depleted G-CSF stimulated bone marrow from partially mismatched related donor who reached engraftment by Day 45.</description>
        <time_frame>Day 45</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Granulocyte Colony Stimulating Factor (G-CSF) Stimulation</title>
            <description>Participants received bone marrow from donors who underwent Granulocyte Colony Stimulating Factor (G-CSF) stimulation prior to bone marrow collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftment Rate</title>
          <description>The number of participants who received in vivo T-cell-depleted G-CSF stimulated bone marrow from partially mismatched related donor who reached engraftment by Day 45.</description>
          <units>particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Acute Graft-versus-host Disease</title>
        <description>The number of participants diagnosed with new acute graft-versus-host disease (GVHD).</description>
        <time_frame>Day 100</time_frame>
        <population>Participants who who developed acute GVHD was measured at Day 100 post bone marrow transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Granulocyte Colony Stimulating Factor (G-CSF) Stimulation</title>
            <description>Participants received bone marrow from donors who underwent Granulocyte Colony Stimulating Factor (G-CSF) stimulation prior to bone marrow collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute Graft-versus-host Disease</title>
          <description>The number of participants diagnosed with new acute graft-versus-host disease (GVHD).</description>
          <population>Participants who who developed acute GVHD was measured at Day 100 post bone marrow transplant.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Chronic Graft-versus-host Disease</title>
        <description>The number of participants diagnosed with chronic graft-versus-host disease (GVHD).</description>
        <time_frame>Duration of Study (Up to two years)</time_frame>
        <population>Participants who survived beyond Day 100 post bone marrow transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Granulocyte Colony Stimulating Factor (G-CSF) Stimulation</title>
            <description>Participants received bone marrow from donors who underwent Granulocyte Colony Stimulating Factor (G-CSF) stimulation prior to bone marrow collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Chronic Graft-versus-host Disease</title>
          <description>The number of participants diagnosed with chronic graft-versus-host disease (GVHD).</description>
          <population>Participants who survived beyond Day 100 post bone marrow transplant.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the duration of the study and follow up period (up to two years).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Granulocyte Colony Stimulating Factor (G-CSF) Stimulation</title>
          <description>Participants with hematologic malignancies or bone marrow failure syndrome received in vivo T-cell depleted granulocyte colony stimulating factor (G-CSF) stimulated bone marrow from a partially mismatched related donor.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Recurrent Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ system failure</sub_title>
                <description>Multi-organ system failure was related to severe graft-versus-host disease and resulted in death.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There was a small number of participants and a short follow up time period for this trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kuang-Yueh Chiang, MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-785-0858</phone>
      <email>kchian2@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

